Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Laura Christine Collins, M.D.

Co-Author

This page shows the publications co-authored by Laura Collins and Judy Garber.
Connection Strength

1.293
  1. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol. 2009 Jul; 33(7):1093-7.
    View in: PubMed
    Score: 0.422
  2. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer. 2021 Oct 26.
    View in: PubMed
    Score: 0.248
  3. DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clin Cancer Res. 2010 Dec 01; 16(23):5796-804.
    View in: PubMed
    Score: 0.117
  4. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):508.
    View in: PubMed
    Score: 0.086
  5. Retinoblastoma protein expression and its predictors in triple-negative breast cancer. NPJ Breast Cancer. 2020; 6:19.
    View in: PubMed
    Score: 0.056
  6. Retinoblastoma protein expression and its predictors in triple-negative breast cancer. NPJ Breast Cancer. 2020 Jun 05; 6(1):19.
    View in: PubMed
    Score: 0.056
  7. Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case-Control Analysis Nested within the Nurses' Health Study II. Cancer Epidemiol Biomarkers Prev. 2020 06; 29(6):1264-1270.
    View in: PubMed
    Score: 0.056
  8. Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS). JNCI Cancer Spectr. 2018 Nov; 2(4):pky063.
    View in: PubMed
    Score: 0.051
  9. Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. NPJ Breast Cancer. 2016; 2:16002.
    View in: PubMed
    Score: 0.042
  10. Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers. Am J Surg Pathol. 2012 Oct; 36(10):1483-8.
    View in: PubMed
    Score: 0.033
  11. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res. 2010; 12(6):R95.
    View in: PubMed
    Score: 0.029
  12. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res. 2010; 12(1):R12.
    View in: PubMed
    Score: 0.028
  13. Determination of factors predicting for estrogen receptor positive (ER+) breast cancers in BRCA1 mutation carriers. J Clin Oncol. 2009 May 20; 27(15_suppl):11045.
    View in: PubMed
    Score: 0.026
  14. Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet. 2007 Nov; 44(11):726-31.
    View in: PubMed
    Score: 0.023
  15. Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005 May; 14(5):1082-9.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.